Patient Access to Innovative New Technologies Act of 2025

Hozzl · 2025-07-24T02:23:24Z

Explore the details of House Bill 4441 Patient Access to Innovative New Technologies Act of 2025 currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on undefined. Stay informed on legislative developments.

7/24/2025, 2:23 AM

Summary of Bill HR 4441

This bill, titled "To amend title XVIII of the Social Security Act to improve Medicare beneficiary access to new medical technologies," was introduced in the 119th Congress as H.R. 4441 on July 16, 2025. Its purpose is to enhance Medicare beneficiary access to innovative medical technologies by allowing breakthrough devices conditional approval under the Medicare New Technology Add-On Payment Program, ensuring timely provision of these advancements to Medicare recipients.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill HR 4441

Bill HR 4441 is currently in the status of Bill Introduced since July 16, 2025. Bill HR 4441 was introduced during Congress 119 and was introduced to the House on July 16, 2025. Bill HR 4441's most recent activity was Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. as of July 16, 2025

Bipartisan Support of Bill HR 4441

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill HR 4441

Primary Policy Focus

Alternate Title(s) of Bill HR 4441

Patient Access to Innovative New Technologies Act of 2025

To amend title XVIII of the Social Security Act to improve Medicare beneficiary access to new medical technologies that improve health care quality and outcomes by ensuring that breakthrough devices are eligible for conditional approval under the Medicare New Technology Add-On Payment (NTAP) Program, enabling these medical breakthroughs to be provided to Medicare beneficiaries without unnecessary delay.